Actively Recruiting
The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine
Led by Anhui Provincial Hospital · Updated on 2026-05-11
96
Participants Needed
1
Research Sites
59 weeks
Total Duration
On this page
Sponsors
A
Anhui Provincial Hospital
Lead Sponsor
T
The First Affiliated Hospital of Anhui Medical University
Collaborating Sponsor
AI-Summary
What this Trial Is About
A multicenter, open-label, randomized, controlled study. It is proposed to evaluate the treatment plan of receiving 930mg polyene phosphatidylcholine injection one day before the operation, twice a day, and 930mg polyene phosphatidylcholine injection twice a day,combined with 100mg of magnesium isoglycyrrhizinate injection once a day,from the 1st to the 5th day after the operation. Compared with the monotherapy regimen of no liver protection treatment before the operation and receiving magnesium isoglycyrrhizinate injection 100mg once a day from the 1st to the 5th day after the operation.The efficacy and safety of treating postoperative liver function injury in patients undergoing laparoscopic hepatectomy for hepatocellular carcinoma were compared.
CONDITIONS
Official Title
The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with hepatocellular carcinoma (HCC) confirmed by imaging and lab tests and eligible for laparoscopic anatomical liver resection
- Planned surgical scope is either major hepatectomy (3 or more liver segments) or minor hepatectomy (2 or fewer segments)
- Use of Pringle method during surgery with 2 to 4 blocks lasting 15 minutes or less each
- Age between 18 and 80 years, any gender, BMI between 18.5 and 28 kg/m²
- Child-Pugh grade A or B with score ≤ 7; ASA physical status grades I to III
- Preoperative ICG R15 less than 10%, and residual liver volume more than 40% of standard liver volume
- Single tumor less than 10 cm in diameter without distant spread or portal vein invasion
- Preoperative ALT less than twice the upper limit of normal
- No history of portal vein embolization before enrollment; if prior TACE treatment, completed more than 6 months ago; if prior systemic anti-tumor therapy, completed more than 4 weeks ago
- No use of liver-damaging drugs within two weeks before enrollment
You will not qualify if you...
- Liver vascular damage such as reconstruction after severance, ligation, embolization, or thrombosis
- Abnormal blood clotting with prothrombin time prolonged by more than 3 seconds
- Presence of obstructive jaundice, severe heart or kidney disease, or other serious illnesses
- Use of microwave treatment or combination with microwave treatment during surgery
- More than 4 blocks of hepatic hilum occlusion or any single block longer than 15 minutes
- Non-anatomic liver resection with ischemic or edematous areas in remaining liver
- Blood transfusion exceeding 1000 ml during surgery
- Discovery of extra-hepatic disease requiring removal of other organs except gallbladder during surgery
- Additional intrahepatic lesions needing combined surgeries during operation
- Prior systemic glucocorticoid treatment for conditions like chronic kidney disease, inflammatory or immune disorders
- Psychosis, severe neurosis, or inability to cooperate with the study
- Participation in another clinical trial within the previous 3 months
- Allergy or intolerance to benzoic acid or study drugs
- Pregnant or breastfeeding women
- Any other condition deemed unsuitable by the researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Anhui Provincial Hospital
Hefei, Anhui, China, 230000
Actively Recruiting
Research Team
L
Lianxin Liu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here